happy and healthy family


Enanta applies its chemistry-driven approach and drug discovery capabilities to developing small molecule cures for viral infections and liver diseases impacting the highest at-risk patient populations. Long before the SARS-CoV-2 pandemic engulfed the world, Enanta always believed that the most profoundly beneficial impact to improve health is to address long-standing gaps in drug development R&D that have inadequately addressed the prevention and treatment of infectious diseases. Enanta’s commitment to ‘reach high’ on behalf of the most at-risk patients has been unyielding. Through our collaboration with AbbVie, we helped discover two cures for hepatitis C and today have novel, potential cures under development for infections of respiratory syncytial virus, SARS-CoV-2 and hepatitis B virus. At Enanta, we are building a leading treatment portfolio for viral respiratory infections. To learn more about participation in Enanta clinical trials, please see below.

Clinical Trials

Enanta is committed to the development of novel treatments for viral infections and liver diseases for patients with serious medical conditions. Enanta has active clinical trial programs in respiratory syncytial virus (RSV) and SARS-CoV-2 (COVID-19).

If you are interested in learning more about Enanta’s current and future clinical trials, please contact:

Through clinical trials we are advancing novel therapeutics for significant respiratory infections.

Respiratory Syncytial Virus


Therapeutic: EDP-235, in clinical development as a potential treatment for COVID-19

Trial Status: Actively Recruiting

Trial Information: EDP-235 is currently enrolling patients in a randomized, double-blind, placebo-controlled, first-in-human study to evaluate the safety, tolerability, and pharmacokinetics of single ascending doses and multiple ascending doses, and the effect of food on EDP-235 pharmacokinetics, in healthy participants.

Read More »

Approximately 60 healthy volunteers aged 18 to 65 years will be enrolled. The first phase assesses single ascending doses of EDP-235 or placebo in healthy subjects. A “fasted” and “fed” two-part cohort will also assess food effect. The second phase assesses multiple ascending doses of EDP-235 or placebo for seven days in healthy subjects. Each cohort within each phase will enroll a total of eight subjects who will be randomized to receive EDP-235 or placebo. Subjects with clinically relevant evidence or history of illness or disease or infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) at screening, or infection with SARS-CoV-2 at screening or the Day 1 visit, are not allowed to participate. Additionally, pregnant or nursing females, those with a history of febrile illness within seven days prior to the first dose of study drug, or subjects with evidence of active infection, are not allowed to enroll. Other exclusion criteria include, but aren’t limited to, a positive urine drug screen at screening or Day 1, current tobacco smokers or tobacco use within three months prior to screening, or a history of regular alcohol consumption.

The primary objective of the study is to evaluate the safety, tolerability and pharmacokinetics of EDP-235 in healthy subjects.

For more information, visit Identifier: NCT05246878

Patient Resources

Respiratory Syncytial Virus (RSV)

American Lung Association logo
American Thoracic logo
CDC logo
healthy children dot org logo
National Foundation for Infectious Diseases logo


CDC logo
Johns Hopkins University logo

Hepatitis B Virus (HBV)

CDC logo
Hepatits B Foundation logo
Hep B United dot org logo
World Hepatitis Alliance logo

Human Metapneumovirus (hMPV)

American Lung Association logo
CDC logo